Target family: Dopamine receptors (type: gpcr)
Target: D<sub>5</sub> receptor

Ligand: 5-hydroxytryptamine (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.5 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: A68930 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6.6 pEC50
Reference (Journal): Differences between A 68930 and SKF 82958 could suggest synergistic roles of D1 and D5 receptors.
Published in: Pharmacol Biochem Behav

Ligand: (+)-ADTN (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: apomorphine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2001), FDA (2004)
Median affinity:  pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: apomorphine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2001), FDA (2004)
Median affinity:  pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: beta-ergocriptine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Median affinity: 6.9 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: bromocriptine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Median affinity: 6.3 pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: bromocriptine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Median affinity: 6.3 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: (+)-butaclamol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.6 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: cabergoline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1996)
Median affinity: 7.7 pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: chlorpromazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1957)
Median affinity: 6.9 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: clozapine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1989)
Median affinity: 6.6 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: dopamine (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: yes
Median affinity: 6.599999904632568 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: ecopipam (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.3 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: flupentixol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Median affinity: 8.1 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: fluphenazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1959)
Median affinity: 7.9 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: haloperidol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967)
Median affinity: 6.3 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: ketanserin (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Median affinity: 5.6 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: lisuride (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2011)
Median affinity: 8.5 pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: noradrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 4.9 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: N-propylnorapomorphine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.9 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: pergolide (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988)
Median affinity:  pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: pergolide (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1988)
Median affinity:  pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: rotigotine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: EMA (2006), FDA (2007)
Median affinity: 6 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: SCH-23390 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: SKF-38393 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 7 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: SKF-76783 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.3 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: (+)-SKF-82526 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.8 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: (-)-SKF-82526 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.1 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: SKF-83566 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.4 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: spiperone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.3 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature

Ligand: [125I]SCH23982 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.1 pKd

Ligand: [3H]SCH-23390 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.2 pKd
Reference (Journal): Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study.
Published in: J Neuroimmunol

Ligand: thioridazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1962)
Median affinity: 5.6 pKi
Reference (Journal): Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Published in: Nature